Antibody Mediated Rejection clinical trials at University of California Health
2 research studies open to eligible people
Showing trials for
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
open to eligible people ages 18-70
This trial investigates the efficacy and safety of clazakizumab [an anti-interleukin (IL)-6 monoclonal antibody (mAb)] for the treatment of CABMR in recipients of a kidney transplant.
at UCLA
VIRTUUS Children's Study
open to eligible people ages 2-18
The objective of the VIRTUUS Children's Study is to adapt identified and validated adult noninvasive diagnostic and prognostic biomarkers for the characterization of allograft status in pediatric recipients of kidney allografts.
at UCLA UCSD
Last updated: